Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Induces
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Bezafibrat, Bezalip, Bezastad; Belgium: Cedur, Eulitop; Cyprus: Lacromid; Czech Republic: Bezalip, Bezamidin, Regadrin; Denmark: Bezafibrat; Finland: Bezalip; France: Befizal; Germany: Befibrat, Bezafibrat, Bezagamma, Cedur, Lipox Bezafibrat Retardtabletten; Greece: Bezalip; Hungary: Bezalip; Ireland: Bezalip; Italy: Bezalip; Luxembourg: Bezacur, Cedur; Netherlands: Bezalip; Poland: Bezalip, Bezamidin; Portugal: Bezalip; Romania: Bezafibrat, Regadrin; Slovenia: Etifibrat; Spain: Difaterol, Eulitop; Sweden: Bezalip; UK: Bezalip.

North America

Canada: Bezalip, Bezafibrate.

Latin America

Argentina: Bezacur, Bezalip, Elpi Lip; Brazil: Bezafibrato, Cedur; Mexico: Befitec, Bexalcor, Bezafibrato, Bezafisal, Bezalex, Bifarén, Bionolip, Colser, Fazebit, Lesbest, Lipocín, Neptalip, Nivetril, Redalip, Safital, Saprame, Zaf.


Japan: Anibesol, Befarlart, Beriatol, Besastar, Betlol, Bezafibrate, Bezalex, Bezalip, Bezasafe, Bezatate, Bezaterio, Bezatol, Bunatol, Busyarlu, Kenperate, Midenal, Modobil, Natoris, Vesturit.

Drug combinations


Bezafibrate: C~19~H~20~ClNO~4~. Mw: 361.82. (1) Propanoic acid, 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl-; (2) 2-[p-[2-(p-Chlorobenzamido)ethyl]phenoxy]-2-methylpropionic acid. CAS-41859-67-0 (1978).

Pharmacologic Category

Antilipemic Agents; Fibric Acid Derivatives. (ATC-Code: C10AB02).

Mechanism of action

Mechanism not established. May increase VLDL catabolism by increasing lipoprotein and hepatic triglyceride lipase activities. May decrease triglyceride biosynthesis by inhibition of acetyl-CoA carboxylase. May decrease cholesterol biosynthesis by inhibition of 3-hydroxy-3-methyglutaryl-coenzyme A reductase.

Therapeutic use

Adjunct to diet and other therapeutic measures for treatment of type II~a~ and II~b~ mixed hyperlipidemia, to regulate lipid and apoprotein levels (reduce serum triglycerides, LDL-C and apolipoprotein B, increase HDL-C and apolipoprotein A). Treatment of adult patients with high to very high triglyceride levels (hypertriglyceridemia)(Fredrickson classification type IV and V hyperlipidemias) who are at high risk of complications from their dyslipidemia.

Pregnancy and lactiation implications

Embryotoxicity reported in animals. Women planning pregnancy should discontinue bezafibrate several months before conception. Contraindicated during lactation.

Unlabeled use


Hypersensitivity to bezafibrate, fibrates, or any component of the formulation. Hepatic or renal dysfunction. Primary biliary cirrhosis. Pre-existing gallbladder disease. Concurrent use of MAO inhibitors. Pregnancy or breast-feeding. Not indicated for the treatment of type I hyperlipoproteinemia.

Warnings and precautions

Hepatotoxic (caution in history of jaundice or hepatic disorder). Has been associated with rare myositis or rhabdomyolysis. Possibly tumorigenic in animals. Caution in renal impairment, hypoalbuminemia, or nephrotic syndrome. Caution with HMG-CoA reductase inhibitors (may lead to myopathy, rhabdomyolysis). Caution with warfarin.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart